IV Pectin Polysaccharides for SARS-CoV-2 Viral Load Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There are no known treatments that effectively lower the infectivity of SARS-COV-2, a single-stranded RNA virus causing COVID-19, which has resulted in significant mortality and transmission.
Innovation Solution
Administering pectin polysaccharides or a pharmaceutical composition thereof to subjects to reduce SARS-COV-2 infectivity by binding to the virus, thereby decreasing the viral load and inhibiting its entry into human cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If no treatment is administered, then the natural course of SARS-COV-2 infection proceeds, but the infectivity and viral load remain high causing severe disease and transmission
Solution Approach 1:
Pectin polysaccharides serve as an intermediary substance that binds to SARS-COV-2 virus particles, forming complexes that are then cleared from the body. This mediator approach reduces viral load and infectivity without directly attacking the virus with cytotoxic agents, thereby resolving the contradiction between reducing harmful viral factors and maintaining treatment reliability.
Solution Approach 2:
The invention changes the physical-chemical parameters of the viral particles through binding with pectin polysaccharides, altering their properties so they can be more effectively cleared by the immune system. This parameter change approach transforms the virus from a harmful state to a cleared state, addressing both the viral load reduction and treatment reliability requirements.
2Reliability
If conventional treatments are used, then standard care is provided, but there is no known treatment that effectively lowers SARS-COV-2 infectivity
Solution Approach 1:
Pectin polysaccharides are derived from natural sources (fruit pectin) and can be produced through straightforward extraction processes. The treatment leverages the body's own immune response mechanisms to clear the virus-after binding, rather than requiring complex pharmaceutical interventions. This self-service approach makes the treatment easily manufacturable and accessible while achieving reliable infectivity reduction.
3Reliability
If pectin polysaccharides are administered frequently (multiple times per day), then viral load reduction is enhanced, but administration complexity and burden increase
Solution Approach 1:
The administration regimen adapts to the patient's needs and response. The treatment can be administered multiple times per day for severe cases or less frequently for mild cases, allowing the protocol to dynamically adjust to individual requirements. This dynamic approach maintains effective viral load reduction while avoiding excessive administration burden.
Solution Approach 2:
The frequency and dosage parameters of pectin polysaccharide administration can be adjusted based on disease severity and patient response. By changing these parameters flexibly, the treatment achieves optimal viral load reduction without imposing excessive administrative complexity, resolving the contradiction between effectiveness and ease of operation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Pectin polysaccharides significantly decrease the viral load and infectivity of SARS-COV-2, as measured by reduced copy numbers of SARS-COV-2 RNA polynucleotides and increased cycle threshold (Ct) values in biological samples, and enhance the immune response by increasing Immunoglobulin G (IgG) antibody titers.
Implementation Method 1
Administering pectin polysaccharides or a pharmaceutical composition thereof to subjects to reduce SARS-COV-2 infectivity by binding to the virus
Implementation Method 2
inhibiting its entry into human cells
Implementation Method 3
enhance the immune response by increasing Immunoglobulin G (IgG) antibody titers
Data Source
AI summary
The invention provides a method for treating SARS-COV-2 by administering an effective amount of pectin polysaccharides to a subject in need thereof.